SAFETY AND TOLERABILITY DURING OPEN-LABEL TREATMENT WITH LCZ696 IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED EJECTION FRACTIO
Not Applicable
Recruiting
- Conditions
- -I50I50
- Registration Number
- PER-034-15
- Lead Sponsor
- OVARTIS BIOSCIENSES PERU S.A.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
1. Written informed consent for the extension must be obtained before any assessment is performed.
2. Patients who have completed PARADIGM-HF and are able to safely transition into the open-label study as judged by the investigator.
Exclusion Criteria
1. Any condition that in the opinion of the investigator is likely
to prevent the patient from safely tolerating LCZ696 or
complying with the requirements of the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method